MAP2K7 and neoplasm: ScRNA-Seq of vehicle- or selumetinib-treated mouse intracranial tumors demonstrated differences in MEK activation, MEK inhibitor sensitivity, and transcriptional programs underlying MEK inhibitor resistance between MES-like and non-MES tumor cell subpopulations.